Page 22 - GTM-3-1

Global Translational Medicine Role of HTS in cancer therapeutics

Availability of data 2017;69(4):479‑496.

Not applicable. doi: 10.1124/pr.117.013755
12. Woodward AA, Urbanowicz RJ, Naj AC, Moore JH. Genetic
References heterogeneity: Challenges, impacts, and methods through
1. Macarron R, Banks MN, Bojanic D, et al. Impact of high- an associative lens. Genet Epidemiol. 2022;46(8):555‑571.
throughput screening in biomedical research. Nat Rev Drug doi: 10.1002/gepi.22497
Discov. 2011;10(3):188‑195.
13. Lawson ARJ, Abascal F, Coorens THH, et al. Extensive
doi: 10.1038/nrd3368 heterogeneity in somatic mutation and selection in the

2. Wigglesworth MJ, Murray DC, Blackett CJ, Kossenjans M, human bladder. Science. 2020;370(6512):75‑82.
Nissink JW. Increasing the delivery of next generation doi: 10.1126/science.aba8347
therapeutics from high throughput screening libraries. Curr
Opin Chem Biol. 2015;26:104‑110. 14. Murphy N, Ward HA, Jenab M, et al. Heterogeneity of
colorectal cancer risk factors by anatomical subsite in 10
doi: 10.1016/j.cbpa.2015.04.006 European countries: A multinational cohort study. Clin
3. Pereira DA, Williams JA. Origin and evolution of high Gastroenterol Hepatol. 2019;17(7):1323‑1331.e6.
throughput screening. Br J Pharmacol. 2007;152(1):53‑61. doi: 10.1016/j.cgh.2018.07.030
doi: 10.1038/sj.bjp.0707373 15. Haffner MC, Zwart W, Roudier MP, et al. Genomic and
4. Shun TY, Lazo JS, Sharlow ER, Johnston PA. Identifying phenotypic heterogeneity in prostate cancer. Nat Rev Urol.
actives from HTS data sets: Practical approaches for the 2021;18(2):79‑92.
selection of an appropriate HTS data-processing method doi: 10.1038/s41585‑020‑00400‑w
and quality control review. J Biomol Screen. 2011;16(1):1‑14.
16. Mitelpunkt A, Galili T, Kozlovski T, et al. Novel Alzheimer’s
doi: 10.1177/1087057110389039 disease subtypes identified using a data and knowledge
5. Dreiman GHS, Bictash M, Fish PV, Griffin L, Svensson F. driven strategy. Sci Rep. 2020;10(1):1327.
Changing the HTS paradigm: AI‑driven iterative screening doi: 10.1038/s41598‑020‑57785‑2
for hit finding. SLAS Discov. 2021;26(2):257‑262.
17. Margineanu DG. Systems biology, complexity, and the
doi: 10.1177/2472555220949495 impact on antiepileptic drug discovery. Epilepsy Behav.
6. Tsoli M, Wadham C, Pinese M, et al. Integration of genomics, 2014;38:131‑142.
high throughput drug screening, and personalized xenograft doi: 10.1016/j.yebeh.2013.08.029
models as a novel precision medicine paradigm for high risk
pediatric cancer. Cancer Biol Ther. 2018;19(12):1078‑1087. 18. Kell DB. Finding novel pharmaceuticals in the systems
biology era using multiple effective drug targets,
doi: 10.1080/15384047.2018.1491498 phenotypic screening and knowledge of transporters:
7. Mayr LM, Bojanic D. Novel trends in high‑throughput where drug discovery went wrong and how to fix it. FEBS J.
screening. Curr Opin Pharmacol. 2009;9(5):580‑588. 2013;280(23):5957‑5980.
doi: 10.1016/j.coph.2009.08.004 doi: 10.1111/febs.12268
8. Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation 19. Ericson E, Gebbia M, Heisler LE, et al. Off-target effects
of high-throughput screening in drug discovery-toxicological of psychoactive drugs revealed by genome-wide assays in
screening tests. Int J Mol Sci. 2012;13(1):427‑452. yeast. PLoS Genet. 2008;4(8):e1000151.
doi: 10.3390/ijms13010427 doi: 10.1371/journal.pgen.1000151
9. Milinkovic A, Martínez E. Nevirapine in the treatment of 20. Lim H, Poleksic A, Yao Y, et al. Large‑scale off‑target
HIV. Expert Rev Anti Infect Ther. 2004;2(3):367‑373. identification using fast and accurate dual regularized
one-class collaborative filtering and its application to drug
doi: 10.1586/14787210.2.3.367
repurposing. PLoS Comput Biol. 2016;12(10):e1005135.
10. FDA. Approved Drugs Generated from High Throughput
Screening Efforts I ‑ 20190719. Rome: FDA; 2019. doi: 10.1371/journal.pcbi.1005135
21. Lin A, Giuliano CJ, Palladino A, et al. Off-target toxicity is a
11. Coussens NP, Braisted JC, Peryea T, Sittampalam GS,
Simeonov A, Hall MD. Small‑molecule screens: A gateway common mechanism of action of cancer drugs undergoing
to cancer therapeutic agents with case studies of food and clinical trials. Sci Transl Med. 2019;11(509):eaaw8412.
drug administration-approved drugs. Pharmacol Rev. doi: 10.1126/scitranslmed.aaw8412

Volume 3 Issue 1 (2024) 14 https://doi.org/10.36922/gtm.2448